Ab­b­Vie preps for an on­slaught of Hu­mi­ra biosim­i­lars in 2023, with Skyrizi and Rin­voq to fill the gap for now

Un­veiled Fri­day morn­ing, Ab­b­Vie’s Q3 re­sults and earn­ings call show a com­pa­ny brac­ing for what could be steep Hu­mi­ra loss­es with the com­ing of biosim­i­lar com­peti­tors ear­ly next year, even as the rest of its im­munol­o­gy fran­chise out­paces ini­tial ex­pec­ta­tions.

Be­gin­ning in Jan­u­ary, Ab­b­Vie’s and the world’s best-sell­ing drug Hu­mi­ra (adal­i­mum­ab) will fi­nal­ly see biosim­i­lar com­pe­ti­tion in the US, with the en­trance of Am­gen’s biosim­i­lar, fol­lowed by Sam­sung, Boehringer, Vi­a­tris, and San­doz launch­ing their ver­sions of adal­i­mum­ab next June and Ju­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER